Shopping Cart
- Remove All
Your shopping cart is currently empty
Tuvonralimab (PSB-205; QL1706), comprising a combination of Iparomlimab and Tuvonralimab [1], functions as a dual immune checkpoint inhibitor through its formulation of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $290 | 2-4 weeks | |
| 5 mg | $747 | 2-4 weeks | |
| 10 mg | $1,200 | 2-4 weeks |
| Description | Tuvonralimab (PSB-205; QL1706), comprising a combination of Iparomlimab and Tuvonralimab [1], functions as a dual immune checkpoint inhibitor through its formulation of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies. |
| Cas No. | 2417649-44-4 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.